Longitudinal change in left ventricular hypertrophy in the elderly on antihypertensive therapy

Connecticut Medicine

Volumn 67, Issue 2, 2003, Pages 67-73

  Ahmad, Aftab ^a   Nawaz, Hafsa M ^b   Nevins, Linda ^c   Nawaz, Haq ^c  

^a Visiting Physicians Association   (United States)

^b Griffin Hospital   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; COMORBIDITY; DEMOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 0037961655     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:22:1561-6.
2. Kahan T: The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998; 16:7:S23-9.
3. Lorell BH, Carabello BA: Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation 2000; 102:4:470-9.
4. Levy D, Garrison RJ, Savage DD, et al: Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 1102:101-7.
5. Siscovick DS Raghunathan TE, Rautaharju P. et al: Clinically silent electrocardiographic abnormalities and risk of primary cardiac arrest among hypertensive patients. Circulation 1996; 94(6): 1329-33.
6. Dunn FG, Pringle SD: Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens 1993. 11(10):1003-10.
7. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78(2):197-202.
8. Verdecchia P, Porcellati C, Reboldi G. et al: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104(17): 2039-44.
9. Haider AW, Larson MG, Benjamin EJ, Levy D: Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32(5):1454-9.
10. Benjamin EJ, Levy D: Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317(3): 168-75.
11. Devereux RB, Okin PM, Roman MJ: Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens 1999; 21(5-6):583-93.
12. De Marchi SF, Allemann Y, Seiler C: Relaxation in hypertrophic cardiomyopathy and hypertensive heart disease: Relations between hypertrophy and diastolic function. Heart 2000; 83(6): 678-84.
13. Agabiti-Rosei E: Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Blood Press Suppl 1997; 2:13-5.
14. Koren MJ, Mensah GA, Balke J, et al: Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertens 1993; 6(10):815-23.
15. Liebson PR, Grandits G, Prineas R, et al: Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1993; 87(2):476-86.
16. Schmieder RE, Messerli FH: Is the decrease in arterial pressure the sole factor for reduction of left ventricular hypertrophy? Am J Med 1992; 92(4B):28S-34S.
17. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275(19):1507-13.
18. Devereux RB, Palmieri V, Sharpe N, et al: Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104(11):1248-54.
19. Grodzicki T, Messerli FH: The heart in the hypertensive elderly. J Hum Hypertens 1998; 12(9):593-7.
20. Teo KK: Risk and management of hypertension-related left ventricular hypertrophy. Drugs 1995; 50(6):959-70.
21. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13(3):564-9.
22. Mulrow CD, Cornell JA, HErrera CR, et al: Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994; 272(24):1932-8.
23. Mulrow C, Lau J, Cornell JA, Brand M: Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2000:2.
24. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2(5): 358-67.
25. Morisco C, Argenziano L, Tozzi N, et al: Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy. Drugs 1993; 46(Suppl 2):88-94.
26. Gosse P, Dallocchio M: Left ventricular hypertrophy: Epidemiological prognosis and associated critical factors. Eur Heart J 1993. 14 Suppl D:16-21.
27. Zabalgoitia M, Rahman SN, Haley WE, et al: Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients <65 to ≥ 65 years of age. Am J Cardiol 1998; 82(5):604-8.
28. Aronow WS, Ahn C, Kronzon I: Prevalence of echocardiographic findings in 554 men and in 1,243 women aged >60 years in a long-term health-care facility. Am J Cardiol 1997; 79(3):379-80.
29. Mandinov L, Eberli FR, Seiler C, Hess OM: Diastolic heart failure. Cardiovasc Res 2000; 45(4):813-25.
30. Kyngas H, Lahdenpera T: Compliance of patients with hypertension and associated factors. J Adv Nurs 1999; 29(4):832-9.
31. Hsia Der E, Rubenstein LZ, Choy GS: The benefits of in-home pharmacy evaluation for older persons. J Am Geriatr Soc 1997; 45(2): 211-4.
32. Munson ML: Characteristics of elderly home health-care users: Data from the 1996 National Home and Hospice Care Survey. Adv Data 1999; (309): 1-11.
33. Mayet J, Shahi M, Foale RA, et al: Racial differences in cardiac structure and function in essential hypertension. BMJ 1994; 308(6935):1011-4.
34. Devereux RB, Okin PM, Roman MJ: Pre-clinical cardiovascular disease and surrogate end-points in hypertension: Does race influence target organ damage independent of blood pressure? Ethn Dis 1998; 8(2):138-48.